Tofersen and the mixed results of treatment for the deadly neurodegenerative disease.
Sutimlimab will reduce the need for red blood cell transfusion due to hemolysis.
The pharmaceutical industry continues to fight hard against the devastating neurodegenerative disease.
Buntanetap acts simultaneously on three neurotoxic proteins responsible for neurodegenerative disorders: amyloid beta, alpha-synuclein, and tau protein.
Nusinersen for the treatment of spinal muscular atrophy will get a follow-up.
The price tag is over $42 billion.
Bristol-Myers Squibb has come up with ozanimod, a direct competitor to Novartis’ fingolimod and siponimod, for the treatment of multiple sclerosis.